Option chain shows key data for CytoMed Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CytoMed Therapeutics.

CytoMed Therapeutics (NASDAQ:GDTC) Stock, Option Chain

CytoMed Therapeutics

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

BOXL

BWNB

COGT

DATS

GDTC

GETY

GORO

HCWC

KUKE

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NARI

RIME

SBEV

SLRN

SYRA

XCUR

XTIA

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

Munich,,Bavaria,,Germany,-,March,31,2023:,Cytomed,Therapeutics,Works

Biotech

News

Health Care

Movers

Trading Ideas

General

CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable immunotherapy solutions.

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

image1 (21)

CytoMed Therapeutics Advances Novel Approach To Transform CAR-T Cell Therapy Access

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics Ltd

Press Releases

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Earnings

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

AAWH

AEMD

ASPI

ATWT

BIDCF

BIXT

BNRG

BTVRF

CMCL

CSE:NTAR

CSE:PMC

CSE:TEX

CVKD

CYIO

ELUT

EUDA

GOEV

GOSS

GOVX

IMRN

INBS

IQST

JETR

LDTC

MTWO

NEXCF

NMHI

NVAAF

PCYO

PENMF

PGEZF

PMCCF

PRSO

RECAF

RGBP

SEVCF

SIGY

SKYH

SUGRF

TRGEF

TSX:VGZ

TSXV:BITK

TSXV:BTV

TSXV:PGE

TSXV:RECO

TSXV:SUG

UMAC

USEG

VANI

XXII

Abpro Hldgs

Allakos

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Cyclo Therapeutics

Equillium

FibroGen

Generation Bio

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Mural Oncology

OSR Holdings

OS Therapies

Ovid Therapeutics

Passage Bio

Pluri

Q32 Bio

Rallybio

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

Benchmark

Comments

CytoMed Therapeutics

CytoMed Therapeutics (GDTC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga